![]() Flow cytometry analysis was conducted to evaluate the apoptosis ratio. Cell proliferation was evaluated through Cell Counting Kit-8 and colony formation assays. Next, osteosarcoma cancerous cell lines SJSA-1 and U2OS were transfected with pcDNA3.1-SRA1 or pCMV-sh-SRA1 to increase or decrease steroid receptor RNA activator 1 expression levels, and microRNA-208a inhibitors, mimic to investigate the effects of microRNA-208a on osteosarcoma as well as the regulatory relation between long noncoding RNA steroid receptor RNA activator 1 and microRNA-208a. Then, quantitative real-time polymerase chain reaction was utilized to validate microarray findings. The aim of this study is to examine long noncoding RNA-steroid receptor RNA activator 1 expression in osteosarcoma to explore the biological function of long noncoding RNA steroid receptor RNA activator 1 on proliferation, migration, and invasion along with apoptosis and its regulatory mechanism, which would facilitate the early diagnosis and targeted therapy of osteosarcoma.įirst, microarray analysis was applied to determine the expression of long noncoding RNAs in osteosarcoma tissues and paired normal tissues. Osteosarcoma is a common malignant bone tumor that is frequently found in the long bones of children and adolescents. Thus, NR2F1-AS1 plays an oncogenic role in OS through sponging miR-483-3p and thereby upregulating FOXA1, suggesting an additional target for osteosarcoma therapeutics. Finally, rescue experiments revealed that knockdown of miR-483-3p and recovery of FOXA1 expression both attenuated the influence of the NR2F1-AS1 knockdown on OS cells. NR2F1-AS1 was found to function as a competing endogenous RNA by directly sponging microRNA-483-3p (miR-483-3p) and upregulating its target oncogene forkhead box A1 (FOXA1). NR2F1-AS1 knockdown inhibited OS cell proliferation, migration, and invasion and promoted cell cycle arrest and apoptosis in vitro and slowed tumor growth in vivo. Patients with OS in an NR2F1-AS1 high-expression group demonstrated significantly shorter overall survival than did patients in an NR2F1-AS1 low-expression group. The increased NR2F1-AS1 level was closely associated with advanced clinical stage and distant metastasis in patients with OS. NR2F1-AS1 was found to be upregulated in OS tumors and cell lines. In this study, we measured NR2F1-AS1 expression in osteosarcoma (OS), determined the involvement of NR2F1-AS1 in the malignant properties of OS, and investigated the underlying mechanisms. The long noncoding RNA NR2F1-AS1 has been found to promote the development of hepatocellular carcinoma and endometrial cancer. This case highlights the utmost role of histopathology in the diagnosis of the bone tumors which would guide the management appropriately. Imaging reveals mainly osteolytic lesions, unlike in conventional OS. Rare histologic variants, especially telangiectatic variant, are more common in younger children and occur more in upper limbs. Very few cases have been reported in <5 years age group and it's relatively rare in 5-10-year-old children. The most common histologic type is osteoblastic/fibroblastic or chondroblastic type. OS occurs more frequently in adolescents around the knee in the metaphyses. She completed her adjuvant chemotherapy and is currently doing well for the past 4 years. The child was started on chemotherapy followed by limb-salvage surgery with wide resection of the tumor in the left proximal humerus. Open biopsy from the left proximal humerus osteolytic lesion suggested clusters of highly atypical cells like osteoid material and focal areas of hemorrhage and necrosis suggestive of TOS. X-ray left shoulder showed osteolytic lesions in the left proximal humerus with fracture of proximal humerus. We report a 6-year-girl who presented with fracture of the left proximal humerus after a trivial trauma. Only few case reports of this rare variant of OS are described in the literature. Telangiectatic osteosarcoma (TOS) is an unusual variant of OS, forming 3-10% of all OSs. OS incidence varies significantly with age and peak incidence is in adolescent age group. Osteosarcoma (OS) is one of the most common primary malignant bone tumors in children and adolescents.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |